David Aaron Lehman Sells 5,765 Shares of Pulmonx Co. (NASDAQ:LUNG) Stock

Pulmonx Co. (NASDAQ:LUNG) General Counsel David Aaron Lehman sold 5,765 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $6.69, for a total transaction of $38,567.85. Following the completion of the sale, the general counsel now directly owns 203,348 shares of the company’s stock, valued at $1,360,398.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Pulmonx Price Performance

Shares of LUNG traded up $0.34 during mid-day trading on Thursday, hitting $6.94. The company’s stock had a trading volume of 418,957 shares, compared to its average volume of 439,800. The firm has a 50-day simple moving average of $6.89 and a 200 day simple moving average of $7.87. Pulmonx Co. has a 1-year low of $5.46 and a 1-year high of $14.84. The firm has a market capitalization of $269.38 million, a P/E ratio of -4.24 and a beta of 0.63. The company has a current ratio of 8.97, a quick ratio of 7.92 and a debt-to-equity ratio of 0.37.

Wall Street Analysts Forecast Growth

LUNG has been the topic of several recent research reports. Lake Street Capital initiated coverage on Pulmonx in a research report on Tuesday, June 4th. They issued a “buy” rating and a $12.00 price target on the stock. Canaccord Genuity Group upped their price target on Pulmonx from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Finally, Wells Fargo & Company lowered their price objective on shares of Pulmonx from $14.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, Pulmonx currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.29.

Institutional Investors Weigh In On Pulmonx

Institutional investors have recently made changes to their positions in the stock. Sei Investments Co. boosted its stake in shares of Pulmonx by 2.5% during the 1st quarter. Sei Investments Co. now owns 72,626 shares of the company’s stock worth $673,000 after acquiring an additional 1,800 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Pulmonx during the fourth quarter worth $156,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Pulmonx by 7.0% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,059,018 shares of the company’s stock worth $6,714,000 after purchasing an additional 69,595 shares in the last quarter. Primecap Management Co. CA grew its holdings in Pulmonx by 2.2% in the fourth quarter. Primecap Management Co. CA now owns 5,646,451 shares of the company’s stock valued at $71,992,000 after purchasing an additional 124,050 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Pulmonx by 0.6% in the first quarter. Vanguard Group Inc. now owns 2,077,859 shares of the company’s stock valued at $19,262,000 after buying an additional 11,417 shares in the last quarter. 91.04% of the stock is currently owned by hedge funds and other institutional investors.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.